
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs Inc. is advancing its product pipeline with promising developments in both infectious disease vaccines and cancer immunotherapies, particularly through its next-generation COVID-19 vaccine, GEO-CM04S1, which has shown positive Phase 2 results in immunocompromised populations. The company benefits from favorable regulatory feedback for its Mpox/Smallpox vaccine and is utilizing a scalable manufacturing platform that addresses previous supply constraints, bolstering its growth potential. Additionally, strategic collaborations and ongoing assessment of gene-directed therapies, in conjunction with major health institutions, highlight Geovax's commitment to expanding its oncology initiatives, strengthening investor confidence in its long-term viability and market position.
Bears say
Geovax Labs faces significant financial challenges, notably a limited cash runway of $5 million at the end of Q3, coupled with high cash burn rates due to ongoing research and development activities. These conditions heighten the execution risk for the company, especially in a funding environment where nearly 40% of public biotechs are projected to exhaust their cash within the next year. Additionally, the elevated risks associated with financing and the depressed share price have led to a reassessment of the company's valuation, lowering it from $9.00 to $6.00 to account for potential dilution and funding uncertainties.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares